Taiwan Bio-Manufacturing Corporation (TBMC) specializes in novel drug modalities, including mRNA vaccines, mRNA therapeutics, and cell and gene therapies. The company is actively advancing its CRDMO services.

In July 2025, TBMC CEO David Chang was interviewed by Nikkei Biotechnology & Business. He shared the company’s core strengths in novel drug modalities and its future business strategy, highlighting TBMC’s plans to further expand its presence in the global biotech market.